Needham Reiterates Buy on Biogen, Maintains $305 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a $305 price target.

February 13, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterated a Buy rating on Biogen and maintained a $305 price target.
The reiteration of a Buy rating and maintenance of a $305 price target by a reputable analyst like Ami Fadia from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Biogen's stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100